ScreenerHero
BSLNBasilea Pharmaceutica AG
SWX · CH · Healthcare · Biotechnology · basilea.com
64.60CHF-1.52%Mkt Cap: 912.51M $P/E: 20.57

Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intrav…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
argenx SE
$61.34BUSDP/E 39.8
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap912.51M $
Enterprise Value826.34M $
Revenue (TTM)282.38M $
Gross Profit220.34M $
Net Income (TTM)45.93M $
Revenue/Share22.95 USD
Last Price64.60 CHF
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees200
CountryCH
SectorHealthcare
IndustryBiotechnology
ISINCH0011432447
Valuation
P/E (Trailing)20.57
P/E (Forward)14.95
PEG-0.08
EV/EBITDA11.88
EV/Revenue2.93
P/S3.21
P/B4.90
EPS (TTM)3.14
EPS (Forward)4.29
52W Range
44.7094% of range65.90
52W High65.90 CHF
52W Low44.70 CHF
Profitability
Gross Margin83.08%
Oper. Margin26.90%
EBITDA Margin24.62%
Profit Margin17.32%
ROE31.45%
ROA14.27%
Growth
Revenue Growth14.50%
Earnings Growth64.40%
Cash Flow & Leverage
Operating CF70.86M $
CapEx (TTM)3.27M $
FCF Margin15.19%
FCF Yield4.70%
Net Debt-102.27M $
Net Debt/EBITDA-1.47
Balance Sheet
Debt/Equity0.70
Current Ratio6.60
Quick Ratio5.81
Book Value/Sh13.09 CHF
Cash/Share13.95 CHF
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CHF
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateApr 11, 2013
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)88.50 CHF
Upside (mean)+37.0%
Target Range59.40 CHF – 126.10 CHF
CHF59.40+37.0% to meanCHF126.10
# Analysts5
Ownership
Shares Out.12.38M
Float12.32M
Insiders0.62%
Institutions30.89%
Technical
SMA 5052.48 (+23.1%)
SMA 20052.89 (+22.1%)
Beta0.41
S&P 52W Chg18.16%
Avg Vol (30d)44.96K
Avg Vol (10d)66.91K
Technical Indicators
RSI (14)87.1
MACD2.0634
MACD Signal0.6150
MACD Hist.+1.4484
BB Upper61.67 CHF
BB Middle53.52 CHF
BB Lower45.38 CHF
BB Width30.42%
ATR (14)1.797 CHF
Vol Ratio (20d)4.03x